Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors
Elisabeth Coart, Stefan Suciu, Pierre Squifflet, Everardo D. Saad, Andriy Moshyk, Gaetan de Schaetzen, Marc Buyse, Jeffrey S. Weber, Alexander M.M. Eggermont, Srividya Kotapati
Topics & Concepts
MedicineOncologyInternal medicineAdjuvantIpilimumabSurrogate endpointAdjuvant therapyClinical trialConfidence intervalMelanomaRandomized controlled trialOverall survivalProportional hazards modelCancerImmunotherapyCancer researchCutaneous Melanoma Detection and ManagementCancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways